Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Eloisi Caldas-Lopes"'
Autor:
Hongliang Zong, Alexander Gozman, Eloisi Caldas-Lopes, Tony Taldone, Eric Sturgill, Sarah Brennan, Stefan O. Ochiana, Erica M. Gomes-DaGama, Siddhartha Sen, Anna Rodina, John Koren III, Michael W. Becker, Charles M. Rudin, Ari Melnick, Ross L. Levine, Gail J. Roboz, Stephen D. Nimer, Gabriela Chiosis, Monica L. Guzman
Publikováno v:
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
Acute myeloid leukemia (AML) is a heterogeneous and fatal disease with an urgent need for improved therapeutic regimens given that most patients die from relapsed disease. Irrespective of mutation status, the development of aggressive leukemias is en
Externí odkaz:
https://doaj.org/article/03d9a17749844c7d85caa19fad88d006
Autor:
Jason P Holland, Eloisi Caldas-Lopes, Vadim Divilov, Valerie A Longo, Tony Taldone, Danuta Zatorska, Gabriela Chiosis, Jason S Lewis
Publikováno v:
PLoS ONE, Vol 5, Iss 1, p e8859 (2010)
The positron-emitting radionuclide (89)Zr (t(1/2) = 3.17 days) was used to prepare (89)Zr-radiolabeled trastuzumab for use as a radiotracer for characterizing HER2/neu-positive breast tumors. In addition, pharmacodynamic studies on HER2/neu expressio
Externí odkaz:
https://doaj.org/article/2b4fe11be30f436baa1d26b56108628c
Publikováno v:
Current Stem Cell Research & Therapy. 14:421-427
CSCs are a population of self-renewing and tumor repopulating cells that have been observed in hematologic and solid tumors and their presence contributes to the development of drug resistance. The failure to eliminate CSCs with conventional therapy
Autor:
Ramesh Balusu, Monica L. Guzman, Peter A. Crooks, Narsimha Reddy Penthala, Shobanbabu Bommagani, Meenakshisundaram Balasubramaniam, Sudhakiranmayi Kuravi, Eloisi Caldas-Lopes
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 29:172-178
A series of novel tetrazole analogues of resveratrol were synthesized and evaluated for their antileukemic activity against an extensive panel of human cancer cell lines and against the MV4-11 AML cell line. These molecules were designed as drug-like
Autor:
Blesida Punzalan, Monica L. Guzman, Gabriela Chiosis, Nagavarakishore Pillarsetty, Nicolas Lecomte, Thomas Ku, Connie W. Batlevi, Jason S. Lewis, Mary L. Alpaugh, Larry Norton, Alexander Bolaender, Jacek Koziorowski, Anas Younes, Eva Burnazi, Komal Jhaveri, Anna Rodina, Mohammad M. Uddin, Gail J. Roboz, Suhasini Joshi, Smit K. Shah, Tai Wang, Mark Dunphy, Anson Ku, Pengrong Yan, Pat Zanzonico, Adriana D. Corben, Yelena Y. Janjigian, Shanu Modi, Tony Taldone, Eloisi Caldas-Lopes, Steven M. Larson, Serge K. Lyashchenko, John F. Gerecitano
Publikováno v:
Cancer Cell
Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic tools. We make use of the kinetic selectivity properties of an imaging probe to visualize and me
Autor:
Oscar Lin, Robert Trondl, Brad Beattie, Ari Melnick, Anna Rodina, Alexander Bolaender, Ross L. Levine, Ethel Cesarman, Pat Zanzonico, Gabriela Chiosis, Pengrong Yan, Chenghua Yang, Jason S. Lewis, Sujata Patil, Tony Taldone, John F. Gerecitano, Leandro Cerchietti, Sarah Kishinevsky, Clifford A. Hudis, Radu I Peter, Fumiko Shimizu, Monica L. Guzman, Matthew Riolo, Mohammad F. Farooq, Erica DaGama Gomes, John Koren, Hardik J. Patel, Hediye Erdjument-Bromage, Gail J. Roboz, Nagavarakishore Pillarsetty, Lorenz Studer, Mark Dunphy, Tai Wang, Hongliang Zong, Shanu Modi, Palak Panchal, Eloisi Caldas-Lopes, Mary L. Alpaugh, Christina Pressl, Chao Xu, Steven M. Larson, Feixia Chu, Adriana D. Corben
Publikováno v:
Nature. 538:397-401
Transient, multi-protein complexes are important facilitators of cellular functions. This includes the chaperome, an abundant protein family comprising chaperones, co-chaperones, adaptors, and folding enzymes—dynamic complexes of which regulate cel
Autor:
Elissa W.P. Wong, Ashish Saxena, Tsann-Long Su, Anisha Chaudhry, Benet Pera, Srikanth R. Ambati, Malcolm A.S. Moore, Jae-Hung Shieh, Eloisi Caldas Lopes
Publikováno v:
Oncotarget
DNA damaging agents cause rapid shrinkage of tumors and form the basis of chemotherapy for sarcomas despite significant toxicities. Drugs having superior efficacy and wider therapeutic windows are needed to improve patient outcomes. We used cell prol
Autor:
Brendan Frett, David Jayabalan, Eloisi Caldas Lopes, Jorge Contreras, Morton Coleman, Jorge Monge, Monica L. Guzman, Naresh Gunaganti, Hong-yu Li, Ruben Niesvizky
Publikováno v:
Cancer Research. 80:5155-5155
Multiple myeloma (MM) is a plasma cell malignancy diagnosed in approximately 30 thousand patients per year and accounts for nearly 12 thousand deaths in the US representing 2% of all cancer-related mortality. Novel agents have increased the survival
Autor:
Ashlesha Muley, Ashish Saxena, Sarah C. Rutherford, Doron Betel, Jennifer Ishii, Xabier Agirre, Angela A. Fachel, Seema Sawh, Pilar M. Dominguez, Eloisi Caldas Lopes, Fabian Correa, Kristy L. Richards, Nyasha Chambwe, Rita Shaknovich, Sheng Li, Yanwen Jiang
The biological role of extracellular vesicles (EVs) in diffuse large B-cell lymphoma (DLBCL) initiation and progression remains largely unknown. We characterized EVs secreted by 5 DLBCL cell lines, a primary DLBCL tumor, and a normal control B-cell s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c450258ccdabb5e2a5eecb7fc56d3cd7
https://europepmc.org/articles/PMC6265635/
https://europepmc.org/articles/PMC6265635/
Autor:
Siddhartha Sen, Tony Taldone, Sarah Brennan, Michael W. Becker, John Koren, Erica M. Gomes-DaGama, Stephen D. Nimer, Ross L. Levine, Hongliang Zong, Eloisi Caldas-Lopes, Gabriela Chiosis, Monica L. Guzman, Alexander Gozman, Charles M. Rudin, Anna Rodina, Gail J. Roboz, Ari Melnick, Eric M. Sturgill, Stefan O. Ochiana
Publikováno v:
Cell reports
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
Cell Reports, Vol 13, Iss 10, Pp 2159-2173 (2015)
SUMMARY Acute myeloid leukemia (AML) is a heterogeneous and fatal disease with an urgent need for improved therapeutic regimens given that most patients die from relapsed disease. Irrespective of mutation status, the development of aggressive leukemi